Rev Bras Oftalmol.2012;71(1):63-69
Wet-amd treatment: a review in the anti-vegf drugs
DOI: 10.1590/S0034-72802012000100013
Neovascular age-related macular degeneration is the leading cause of severe, irreversible vision loss in individuals over 50 years in developed countries. Vascular endothelial growth factor (VEGF) has been shown to play a role in the regulation of choroidal neovascularization and vascular permeability. Anti-VEGF drugs have been shown to preserve or improve visual acuity by inhibiting vascular permeability and arresting the growth of neovascularization in the vast majority of treated patients. This review describes the current literature on the use of this therapeutic approach in the management of neovascular AMD and gives an overview of the future directions.
Wet-amd treatment: a review in the anti-vegf drugs